Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin’s lymphoma

Kılıçkap, Saadettin; Yavuz, Bünyamin; Aksoy, Sercan; Şahiner, Levent; Dinçer, Murat; Harputluoğlu, Hakan; Erman, Mustafa; Aytemir, Kudret; Tokgözoğlu, Lâle; Barışta, İbrahim

doi:10.1007/s12032-008-9062-2

Cited by 29 publications

(20 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Limat et al [9] found a reduction in LVEF of over 15% in 20% of patients treated with CHOP, without Rituximab, in a population similar to ours in age and cardiac risk factors. Kilickap et al, in 14 patients treated with R-CHOP versus 14 with CHOP alone, found a decrease in diastolic function that was similar in both arms, without change in the parameters of systolic function [10]. Elbl et al, in 47 patients treated with CHOP, without rituximab, described a frequent subclinical cardiac impairment: 23% of patients had a drop in ejection fraction 410% during the follow-up [11].…”

Section: Discussionmentioning

confidence: 99%

A prospective study of left ventricle function after treatment with rapid-infusion Rituximab in patients with non-Hodgkin lymphoma

Provencio

Sánchez

Maximiano

et al. 2009

Leukemia & Lymphoma

View full text Add to dashboard Cite

We designed a prospective study to measure the left ventricular ejection fraction of 42 patients with non-Hodgkin lymphoma treated with Rituximab-based chemotherapy in a 1-h infusion. Our patients were not selected on the basis of their cardiac status. Cardiac history and other forms of co-morbidity were to be identified on entry. Before treatment, basal left ventricular ejection function (LVEF) was measured and every 6 months after treatment. Most patients were treated with CHOP-Rituximab combinations (79%). A drop in the post-treatment ejection fraction of over 10% from the pre-treatment base figure was found in 13 patients (31% of the total of the series, 39% of those receiving adriamycin-based chemotherapy). None of the patients without adriamycin had a decrease in LVEF. Three patients with drop >10% recovered normally, but when LVEF decreased by over 15%, which occurred in six patients (14.2%), none of them recovered normal level. Patients with normal systolic function had LVEF with a mean of 64.09 (+/-3.86) and patients with decreased systolic function had LVEF with a mean of 59.38 (+/-5.43). Though the data in this study suggest that rapid-infusion Rituximab does not cause relevant cardiac toxicity, there was a high percentage of reductions in LVEF of over 10%.

show abstract

Section: Discussionmentioning

confidence: 99%

A prospective study of left ventricle function after treatment with rapid-infusion Rituximab in patients with non-Hodgkin lymphoma

Provencio

Sánchez

Maximiano

et al. 2009

Leukemia & Lymphoma

View full text Add to dashboard Cite

show abstract

“…For instance, the addition of RTX to CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristineoncovin and prednisolone) did not increase the risk of doxorubicin-induced cardiotoxicity [97]. Siano et al did not find any cardiac toxic effect of RTX treatment, monitoring troponin, BNP, echocardiogram and electrocardiogram, even with a fast infusion rate in patients having received at least one RTX in the previous three months [98].…”

Section: Rituximab May Cause Acute Infusion Reactionsmentioning

confidence: 98%

Biologics and the Cardiovascular System: A Double-Edged Sword

Roubille

Martel‐Pelletier²,

Tardif³

et al. 2013

AIAAMC

View full text Add to dashboard Cite

Abstract:Patients with chronic inflammatory diseases such as rheumatoid arthritis have a higher risk of cardiovascular diseases and related mortality compared to the general population. This risk is first due to classical cardiovascular risk factors but also due to systemic inflammation which is independently involved, causing accelerated atherosclerosis, myocardial infarction, cerebrovascular disease and heart failure (HF). Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 and IL-6 could be major actors on this pathophysiology. Biologics are effective specific treatments in the management of inflammatory rheumatic and systemic diseases. In this review, beneficial and deleterious effects on the heart and vessels of the biologics used in the management of inflammatory arthritis and vasculitides will be discussed, focusing on TNF-alpha, IL-6 and IL-1 blockades, and anti-CD20. Noninflammatory cardiac conditions, such as heart failure, myocardial infarction, and cardiovascular conditions such as atherosclerosis, as well as inflammatory diseases including vasculitides will be discussed.

show abstract

“…Sinus bradycardia [64] Sunitinib, sorafenib AV conduction disturbances [83] Bortezomib Complete AV block Sinus bradycardia [86,88,[90][91][92] [88]…”

Section: Fludarabinementioning

confidence: 99%

“…The global incidence of these events is modest against its large clinical use also in association inside poly-chemotherapeutic regimens with other cardiotoxic drugs, e.g., doxorubicin, cyclophosphamide [92]. Risk factors for rituximab cardiotoxicity may be represented by basal respiratory and cardiovascular diseases.…”

Section: Rituximabmentioning

confidence: 99%

Antineoplastic drug-induced bradyarrhythmias

Minoia¹,

Giannoccaro²,

Iacobazzi³

et al. 2012

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin’s lymphoma

Abstract: Both CHOP and R-CHOP cause diastolic dysfunction in the early period following their administration. The addition of rituximab to CHOP chemotherapy does not significantly increase the risk of doxorubicin-induced cardiotoxicity during this period.

Cited by 29 publications

References 28 publications

A prospective study of left ventricle function after treatment with rapid-infusion Rituximab in patients with non-Hodgkin lymphoma

A prospective study of left ventricle function after treatment with rapid-infusion Rituximab in patients with non-Hodgkin lymphoma

Biologics and the Cardiovascular System: A Double-Edged Sword

Antineoplastic drug-induced bradyarrhythmias

Contact Info

Product

Resources

About